XKH001 / Kanova Biopharma - LARVOL DELTA

First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers. (PubMed, Expert Opin Investig Drugs) - "XKH001 showed favorable safety and pharmacokinetics profiles and a low immunogenicity in its first-in-human study. The data support its further clinical evaluation in patients with type 2 inflammatory diseases."

Clinical • Journal • P1 data • PK/PD data • Inflammation

XKH001 Injection in Healthy Subjects (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Beijing Kanova Biopharmaceutical Co., LTD | Initiation date: Sep 2023 ➔ Dec 2023

Trial initiation date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • CXCL1

XKH001 Injection in Healthy Subjects (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Beijing Kanova Biopharmaceutical Co., LTD

New P1/2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • CXCL1

Phase I of XKH001Injection in Healthy Adults (clinicaltrials.gov) - P1 | N=35 | Active, not recruiting | Sponsor: Beijing Kanova Biopharmaceutical Co., LTD | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Oct 2024

Enrollment closed • Trial completion date • Trial primary completion date

Phase I of XKH001Injection in Healthy Adults (clinicaltrials.gov) - P1 | N=35 | Recruiting | Sponsor: Beijing Kanova Biopharmaceutical Co., LTD | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2022 ➔ Dec 2022 | Trial primary completion date: Jul 2022 ➔ Dec 2022

Enrollment open • Trial completion date • Trial primary completion date